Platinum-based amphiphile prodrugs
AssigneeNanomed Holdings Pty Ltd
InventorsMinoo Jalili MOGHADDAM, Xiaojuan GONG, Ross Cyril SMITH
Life of this patent
Estimating the term…
Abstract
The present invention relates to platinum (IV) prodrug lipid-based amphiphiles and compositions thereof. In particular, it relates to cisplatin, oxaliplatin and carboplatin prodrugs with the capacity to make stable liquid crystalline nanoparticles and crystalline nanoparticles, and uses thereof to treat cancer in animals, including humans.
Claims18
A prodrug of general formula I:
- X1—Y1—A-(Y2)n—X2 (I)
- wherein A is an oxidised platinum (IV)-based therapeutically active agent;
- Y1 and Y2 are independently selected cleavable bonds between X1 and X2, respectively, and A;
- n=0 or 1, wherein when X2 is a substituent according to formula (a), (b), or (c), n is 1;
- X1 is selected from the group consisting of a substituent according to formula (a), a substituent according to formula (b), and a substituent according to formula (c):
- R— (a)
- R—S— (b)
- R—S-L (c)
- X2 is selected from the group consisting of H, a substituent according to formula (a), a substituent according to formula (b), and a substituent according to formula (c):
- R— (a)
- R—S— (b)
- R—S-L (c)
- wherein
- R is selected from the group consisting of alkyl, alkenyl, alkynyl, branched alkyl, branched alkenyl, branched alkynyl, substituted alkyl, substituted alkenyl, substituted alkynyl groups, and their analogues;
- S is selected from the group consisting of (polyethylene glycol)m, wherein m=1-10, an amino acid, and an ethanolamide functionalised amino acid;
- L is a linker group that is covalently attached to S—R at one attachment site and to the therapeutically active agent A at a second attachment site via the bond Y to A.
A method of modulating the bioavailability and release of a platinum-based therapeutically active agent or an agent capable of being metabolised in vivo to a platinum-based therapeutically active agent, the method comprising covalently linking an oxidised platinum (IV)-based therapeutically active agent, A, to at least one tail component, X, to form an amphiphile capable of self-assembling into a self-assembled structure under physiological conditions, and wherein the amphiphile is cleavable in vivo to release the therapeutically active agent, wherein the amphiphile is of general formula (I):
- X1—Y1-A-(Y2)n—X2 (I)
- wherein
- Y1 and Y2 are independently selected cleavable bonds between X1 and X2, respectively, and A;
- n=0 or 1, wherein when X2 is a substituent according to formula (a), (b), or (c), n is 1;
- X1 is selected from the group consisting of a substituent according to formula (a), a substituent according to formula (b), and a substituent according to formula (c):
- R— (a)
- R—S— (b)
- R—S-L (c)
- X2 is selected from the group consisting of H, a substituent according to formula (a), a substituent according to formula (b), and a substituent according to formula (c):
- R— (a)
- R—S— (b)
- R—S-L (c)
- wherein
- R is selected from the group consisting of alkyl, alkenyl, alkynyl, branched alkyl, branched alkenyl, branched alkynyl, substituted alkyl, substituted alkenyl, substituted alkynyl groups, and their analogues;
- S is selected from the group consisting of (polyethylene glycol)m, wherein m=1-10, an amino acid, and an ethanolamide functionalised amino acid;
- L is a linker group that is covalently attached to S—R at one attachment site and to the therapeutically active agent A at a second attachment site via the bond Y to A.
Dependencies are inferred from the claim text.